Legend Biotech
LEGN
160 hedge funds and large institutions have $3.28B invested in Legend Biotech in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 81 increasing their positions, 47 reducing their positions, and 22 closing their positions.
143% more call options, than puts
Call options by funds: $18.5M | Put options by funds: $7.63M
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
72% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 47
1.22% more ownership
Funds ownership: 19.1% → 20.32% (+1.2%)
3% more capital invested
Capital invested by funds: $3.18B → $3.28B (+$104M)
6% less funds holding
Funds holding: 170 → 160 (-10)
45% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$61.3M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$44.7M |
| 3 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
+$24.5M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$23.9M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$23.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$35.7M |
| 2 |
EFM
E Fund Management
Guangzhou,
China
|
-$19.4M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$16.7M |
| 4 |
D.E. Shaw & Co
New York
|
-$13.8M |
| 5 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$13.8M |
LEGN Hedge Fund Activity: Q1 2023 in Review
160 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q1 2023, worth a combined $3.28B — up 3.3% from $3.18B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of LEGN and 12 opened new positions — a net loss of 10 holders — while 47 trimmed existing stakes and 81 added.
The largest buyer was Fidelity Investments, adding an estimated $61.3M. The largest seller was Farallon Capital Management, cutting an estimated $35.7M.
- 160 institutional investors held Legend Biotech (LEGN) as of Q1 2023, down from 170 in Q4 2022.
- Funds reported $3.28B of Legend Biotech stock for Q1 2023, up 3.3% quarter-over-quarter.
- 12 funds opened new Legend Biotech positions in Q1 2023 and 22 closed out, a net change of -10 holders.
- The largest Legend Biotech buyer in Q1 2023 was Fidelity Investments, an estimated $61.3M added.
- The largest Legend Biotech seller in Q1 2023 was Farallon Capital Management, an estimated $35.7M sold.
Based on aggregated 13F filings for Q1 2023.